AZD-3458 (PI3Kγ inhibitor 3) is a novel, potent, orally bioavailable and highly isoform selective PI3Kγ inhibitor with anticancer activity. It has pIC50s of 9.1, 5.1,<4.5, and 6.5 for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively. It has ADME properties suitable for oral administration. Compound 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.